1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Chordate Medical receives market authorization for the migraine indication in Saudi Arabia

Chordate Medical announces that the Saudi Food and Drug Authority (SFDA) has approved the application for market authorization for the migraine indication of the Ozilia®Migraine product system. This means that Chordate and the distributor Janin Medical can initiate the introduction of Ozilia® in the migraine market in Saudi Arabia.

"Saudi Arabia's competent authority, SDFA, is undergoing rapid development, which for us means more bureaucracy, but also better predictability. It is therefore very gratifying that our application was approved earlier than expected. Janin, together with our General Manager in Jeddah, has been processing customer prospects for some time, and we can now immediately begin the introduction of the migraine treatment in the market," says Anders Weilandt, CEO of Chordate.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Chordate Medical receives market authorization for the migraine indication in Saudi Arabia

Datum 2024-10-14, kl 08:30
Källa MFN
Bifogade filer
Chordate Medical receives market authorization for the migraine indication in Saudi Arabia